Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : iCP-NI
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Labcorp
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ICP-NI is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
February 23, 2023
Lead Product(s) : iCP-NI
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Labcorp
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : iCP-NI
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cellivery, iCP-NI 'Corona 19' Primate Treatment Efficacy Verification Begins
Details : The new drug iCP-NI begins to verify the efficacy of treatment for the treatment of acute pneumonia and severe sepsis caused by corona19.
Product Name : iCP-NI
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 27, 2020
Lead Product(s) : iCP-NI
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable